Published in Br J Radiol on February 01, 2013
The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol (1989) 5.78
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys (1982) 2.69
Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys (1982) 2.05
The assessment of RBE effects using the concept of biologically effective dose. Int J Radiat Oncol Biol Phys (1999) 1.58
The incorporation of the concept of minimum RBE (RbEmin) into the linear-quadratic model and the potential for improved radiobiological analysis of high-LET treatments. Int J Radiat Biol (2007) 1.17
Recent advances in light ion radiation therapy. Int J Radiat Oncol Biol Phys (2004) 1.14
Why more needs to be known about RBE effects in modern radiotherapy. Appl Radiat Isot (2008) 1.09
Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br J Radiol (2006) 1.02
A general frmula for equating protracted and acute regimes of radiation. Br J Radiol (1969) 0.96
The apparent increase in the {beta}-parameter of the linear quadratic model with increased linear energy transfer during fast neutron irradiation. Br J Radiol (2009) 0.96
Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. Phys Med Biol (2010) 0.87
Some radiobiological considerations in radiotherapy. Br J Radiol (1961) 0.80
The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol (1985) 3.17
The role of biologically effective dose (BED) in clinical oncology. Clin Oncol (R Coll Radiol) (2001) 1.35
A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol (R Coll Radiol) (1996) 1.31
Fast neutron relative biological effects and implications for charged particle therapy. Br J Radiol (2011) 1.13
Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer (1989) 1.12
A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: studies on the effect of clonogenic cell density. Br J Radiol (2006) 1.12
The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol (2003) 1.11
Mathematical models of tumour and normal tissue response. Acta Oncol (1999) 1.07
The assessment of the body distribution of yttrium-90 ferric hydroxide during radiation synovectomy. Br J Radiol (1976) 1.07
Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer (1988) 1.06
Calculation of high-LET radiotherapy dose required for compensation of overall treatment time extensions. Br J Radiol (2006) 1.02
A theoretical investigation into the role of tumour radiosensitivity, clonogen repopulation, tumour shrinkage and radionuclide RBE in permanent brachytherapy implants of 125I and 103Pd. Phys Med Biol (2001) 0.91
The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol (2005) 0.89
Comments on Inadequacy of iridium implant as sole radiation treatment for operable breast cancer, Fentiman et al., Eur J Cancer 1996, 32A, pp. 608-611. Eur J Cancer (1997) 0.87
Active minimisation of radiation scatter during breast radiotherapy: management implications for young patients with good-prognosis primary neoplasms. Radiother Oncol (1996) 0.87
The potential impact of relative biological effectiveness uncertainty on charged particle treatment prescriptions. Br J Radiol (2011) 0.87
Fractionation effects in particle radiotherapy: implications for hypo-fractionation regimes. Phys Med Biol (2010) 0.87
Cell loss factors and the linear-quadratic model. Radiother Oncol (1995) 0.86
Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.85
Use of second antibody in radioimmunotherapy. NCI Monogr (1987) 0.84
Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) (1997) 0.82
High dose rate brachytherapy practice for the treatment of gynaecological cancers in the UK. Br J Radiol (1999) 0.82
Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol (2008) 0.81
Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. Med Phys (1983) 0.81
The reduction of tumour control with increasing overall time: mathematical considerations. Br J Radiol (1996) 0.80
Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy. Phys Med Biol (2006) 0.80
Determination of the optimum dose per fraction in fractionated radiotherapy when there is delayed onset of tumour repopulation during treatment. Br J Radiol (2004) 0.80
Particle radiotherapy in the UK. Clin Oncol (R Coll Radiol) (2007) 0.80
Results of a questionnaire regarding the practice of radiotherapy for carcinoma of the cervix in the UK. Br J Radiol (1994) 0.80
Estimation of optimum dose per fraction for high LET radiations: implications for proton radiotherapy. Int J Radiat Oncol Biol Phys (2000) 0.80
Derivation of the optimum dose per fraction from the linear quadratic model. Br J Radiol (1995) 0.79
Radiobiological modeling and clinical trials. Int J Radiat Oncol Biol Phys (2000) 0.79
The potential of ytterbium 169 in brachytherapy: a brief physical and radiobiological assessment. Br J Radiol (1992) 0.78
Radiobiological compensation of treatment errors in radiotherapy. Br J Radiol (2008) 0.78
Repair kinetic considerations in particle beam radiotherapy. Br J Radiol (2011) 0.78
A graphical method to simplify the application of the linear-quadratic dose-effect equation to fractionated radiotherapy. Br J Radiol (1986) 0.78
Inclusion of molecular biotherapies with radical radiotherapy: modeling of combined modality treatment schedules. Int J Radiat Oncol Biol Phys (1999) 0.78
Radiobiological prediction of normal tissue toxicities and tumour response in the radiotherapy of advanced non-small-cell lung cancer. Br J Cancer (1998) 0.78
Radiobiologically based assessments of the net costs of fractionated focal radiotherapy. Int J Radiat Oncol Biol Phys (1998) 0.77
Pulsed brachytherapy: a modelled consideration of repair parameter uncertainties and their influence on treatment duration extension and daytime-only "block-schemes". Br J Radiol (2011) 0.75
Regarding Giap and Massullo, IJROBP 1999;45:1355-1358. Int J Radiat Oncol Biol Phys (2000) 0.75
Comment on "Analysis of factors affecting the therapeutic gain in high dose rate gynecological implants relative to low dose rate implants" [Med. Phys. 23, 419-425 (1996)]. Med Phys (1996) 0.75
The BJR and progress in radiobiological modelling. Br J Radiol (2010) 0.75
Conventional wisdom and activities of the middle range. Br J Radiol (2005) 0.75
Case report: low dose rate and high dose rate intracavitary brachytherapy in a patient with carcinoma of the cervix. Br J Radiol (1996) 0.75
Revisions to radial dose function data for 125I and 131Cs. Med Phys (1987) 0.75
Radiobiology of changes in dose-rate. Sonderb Strahlenther Onkol (1988) 0.75
Proceedings: The relationship between iso-effect dose and overall irradiation time in an organized tissue. Br J Radiol (1975) 0.75
Accelerated fractionation (AF) in head and neck cancers. Radiother Oncol (1998) 0.75
Radial dose function (RDF) Int J Radiat Oncol Biol Phys (1989) 0.75
Calculation by computer of dose distributions for superficial gold-198 implants and the derivation of optimized distribution rules. Br J Radiol (1976) 0.75
BED-time charts and their application to the problems of interruptions in external beam radiotherapy treatments. Int J Radiat Oncol Biol Phys (1999) 0.75
A mathematical model of intraluminal and intracavitary brachytherapy. Br J Radiol (1994) 0.75
Plasma TGFbeta1 during pelvic radiotherapy for gynaecological malignancy. Acta Oncol (2006) 0.75
Implications of overall time in radiotherapy. Clin Oncol (R Coll Radiol) (1993) 0.75
A Fortran program for fast and compact processing of clinical radiotherapy data. Comput Biol Med (1984) 0.75
Estimation of tumour hypoxic fraction from clinical data sets compatible with accelerated repopulation. Acta Oncol (1998) 0.75
Quality control of linear accelerator x-ray performance using semiconductor probes. Radiology (1985) 0.75
Implementation of the Philips treatment planning system for use in radiation teletherapy. Br J Radiol (1978) 0.75
A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90. Phys Med Biol (2006) 0.75
Radiobiological compensation for unintended treatment interruptions during palliative radiotherapy. Br J Radiol (2007) 0.75
The incorporation of specific tissue/nuclide attenuation data into the Anderson method for producing brachytherapy volume-dose histograms. Phys Med Biol (1990) 0.75
A Monte Carlo derivation of parameters for use in the tissue dosimetry of medium and low energy nuclides. Br J Radiol (1982) 0.75